Sagimet Biosciences to Present at Two Key Investor Conferences in February 2026
Event summary
- Sagimet Biosciences will participate in Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11, 2026, with a fireside chat at 10am ET.
- The company will also present at Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, with a fireside chat at 9:20am ET.
- Both fireside chats will be available on Sagimet’s website for 90 days post-event.
- Sagimet is developing denifanstat and TVB-3567, two oral FASN inhibitors targeting metabolic and fibrotic pathways.
The big picture
Sagimet Biosciences is positioning itself as a key player in the development of novel therapeutics for metabolic and fibrotic diseases. The company’s participation in high-profile investor conferences underscores its focus on engaging with the investment community to highlight its clinical-stage pipeline, particularly denifanstat and TVB-3567. The broader biotech sector is watching closely as Sagimet advances its FASN inhibitors, which target conditions like MASH and acne, areas with significant unmet medical needs.
What we're watching
- Clinical Progress
- How the Phase 1 PK trial results for the denifanstat and resmetirom combination will impact Sagimet’s strategy for cirrhotic MASH patients.
- Market Positioning
- Whether Sagimet can leverage its FASN inhibitors to compete effectively in the crowded metabolic and fibrotic disease space.
- Investor Sentiment
- The pace at which investor interest in Sagimet’s pipeline grows following these conference presentations.